Biomimetic ECM™

ECM is the microenvironment for cell growth, proliferation and normal physiological functions, playing a decisive role in the regeneration, differentiation, maturation and apoptosis of tissue cells. ECM acts as a "highway" for intercellular communication and cell migration. When skin is damaged or locally infected, repair-related cells such as inflammatory cells and fibroblasts rapidly migrate and gather at the injury site to carry out cleanup, repair and healing.

Biomimetic ECM technology: a high-end combination of modern synthetic biology and advanced chemical manufacturing. Supported by cutting-edge technology, every cell can obtain a "perfect home"

Composition Information

Literature & Patents

Patent No.: ZL201911003706.2
Patent No.: ZL202011232576.2
Patent No.: ZL202010139061.1
Patent No.: ZL202011222280.2
Patent No.: ZL202010081766.2

Mechanism of Action

1. ECM microenvironment remodeling pathway: Construct a 3D extracellular matrix network similar to native human tissue, serving as mechanical scaffold and signal hub to provide suitable microenvironment for cells and guide cell adhesion, homing, proliferation and migration.
2. Soothing & repairing pathway: Downregulate pro-inflammatory factor IL‑6 expression, promote M2 macrophage-associated expression, reduce inflammatory level at injury site and optimize local microenvironment.
3. Anti-aging matrix homeostasis pathway: Downregulate MMP‑1 expression to slow collagen degradation; upregulate TGF‑β1 to boost collagen and elastin synthesis. It bidirectionally regulates matrix anabolism and catabolism, improves dermal ECM degeneration and relieves skin laxity and wrinkles.
4. Cell regulation pathway: Assist in recruiting basal stem cells, promote fibroblast adhesion, spreading and migration; improve the status of UV-aged damaged fibroblasts and restore their healthy spindle morphology.
5. Nano functional system: Nanogel penetrates into the dermis via hair follicles, sweat glands, intercellular spaces and transcellular endocytosis-exocytosis transport to exert activity.

Experimental Data

1. IL‑6 inflammatory cytokine inhibition test: Compared with hyaluronic acid and collagen groups, biomimetic ECM reduces IL‑6 expression at damaged sites by more than 30%.
2. MMP‑1 inhibition test (L929 cells): It significantly downregulates MMP‑1 expression. Matrix degradation level recovers to 96–110% of healthy cells to reduce collagen breakdown.
3. TGF‑β1 upregulation test (L929 cells): It upregulates TGF‑β1 expression, and matrix synthesis capacity recovers to 80–95% of healthy cells.
4. Fibroblast adhesion test: Cells in biomimetic ECM group fully spread in spindle shape with abundant filopodia. Its cell adhesion-promoting performance is markedly superior to hyaluronic acid and PGA/HA.
5. Cell scratch migration test: It greatly enhances fibroblast migration, while hyaluronic acid shows almost no migration-promoting effect.
6. UV-damaged fibroblast model test: It restores flat, morphologically disordered senescent damaged fibroblasts into spindle-shaped healthy cell morphology.